Systemic corticosteroids for subcutaneous panniculitis‐like T‐cell lymphoma. (2nd September 2014)

• Record Type: Journal Article
• Authors: Guenova, E.; Schanz, S.; Hoetzenecker, W.; DeSimone, J.A.; Mehra, T.; Voykov, B.; Urosevic‐Maiwald, M.; Berneburg, M.; Dummer, R.; French, L.E.; Kerl, K.; Kamarashev, J.; Fierlbeck, G.; Cozzio, A.
• Is Part Of: British journal of dermatology. Volume 171:Number 4(2014:Oct.)
• Page Start: 891
• Page End: 894
• Publication Date: 2014-09-02
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.13053
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="main" id="bjd13053-abs-0001"> <title>Summary</title> <sec id="bjd13053-sec-0001" sec-type="section"> <title>Background</title> <p>Primary cutaneous γ/δ T‐cell lymphoma (PCGD‐TCL) is aggressive and has a poor prognosis. In contrast, subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) of the α/β T‐cell receptor phenotype is known to follow an indolent course and have a more favourable prognosis. In the past, PCGD‐TCL and SPTCL were often considered to be a manifestation of the same disease, and aggressive systemic polychemotherapy has commonly been the first‐line therapy for both. Given the understanding that SPTCL is a separate and less aggressive entity, clinical data exclusively evaluating the efficacy of conservative treatment in SPTCL are needed.</p> </sec> <sec id="bjd13053-sec-0002" sec-type="section"> <title>Objectives</title> <p>To assess the overall clinical response to systemic corticosteroids in the treatment of SPTCL.</p> </sec> <sec id="bjd13053-sec-0003" sec-type="section"> <title>Methods</title> <p>This was a retrospective cross‐sectional study based on a patient data repository from two tertiary care university hospitals in Zürich (Switzerland) and Tübingen (Germany). The repository spanned 13 years.</p> </sec> <sec id="bjd13053-sec-0004" sec-type="section"> <title>Results</title> <p>In four of the five patients (80%) with SPTCL, treatment with systemic corticosteroids induced a complete remission.</p> </sec> <sec id="bjd13053-sec-0005" sec-type="section"> <title>Conclusions</title> <p>Systemic corticosteroids may be an excellent first‐line single‐agent therapy for SPTCL.</p> </sec> </abstract>